BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
3.090
-0.360 (-10.43%)
At close: Aug 14, 2026, 4:00 PM EDT
3.110
+0.020 (0.65%)
After-hours: Aug 14, 2026, 7:34 PM EDT
BioAtla Revenue
In the year 2025, BioAtla had annual revenue of $2.00M, down -81.82%.
Revenue (ttm)
$2.00M
Revenue Growth
-81.82%
P/S Ratio
0.60
Revenue / Employee
$207,317
Employees
41
Market Cap
5.13M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00M | -9.00M | -81.82% |
| Dec 31, 2024 | 11.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 250.00K | -179.00K | -41.72% |
| Dec 31, 2020 | 429.00K | -4.77M | -91.75% |
| Dec 31, 2019 | 5.20M | -5.43M | -51.07% |
| Dec 31, 2018 | 10.63M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 4.70M |
| GeoVax Labs | 852.28K |
| CollPlant Biotechnologies | 389.00K |
| BioRestorative Therapies | 357.87K |
| Addex Therapeutics | 136.51K |
| Cardio Diagnostics Holdings | 14.45K |
| Pulmatrix | 3.00K |
BCAB News
- Just now - BioAtla Quarterly report: Q2 2026 - Filings
- 2 months ago - BioAtla Proxy statement: Proxy filing - Filings
- 2 months ago - BioAtla Proxy statement: Proxy filing - Filings
- 3 months ago - Context Therapeutics enters license agreement amendment with BioAtla - TheFly
- 3 months ago - BioAtla Quarterly report: Q1 2026 - Filings
- 4 months ago - BioAtla trading halted, news pending - TheFly
- 4 months ago - BioAtla announces 50-for-1 share consolidation - TheFly
- 4 months ago - BioAtla Announces Share Consolidation - GlobeNewsWire